CareAcross is a community for anyone affected by cancer. It is private, free to join, and full of people who understand

Sign in to CareAcross

If you already have an account at CareAcross, please sign in

Invalid Email or Password

Forgot your password?

Remember me

SIGN UP

CareAcross is a community open to anyone affected by cancer: a private and safe place to share practical tips and personal experiences.
By joining you can also find answers to questions, provided by experienced doctors - and even ask your own question.

The purpose of the study is to identify specific genes that are up- or downregulated in multiple myeloma patients who receive a microdose of either Melphalan (Alkeran®), Bortezomib (Velcade®) or Dexamethasone (Dexaven®). The study treatment constitutes 1% of the planned standard myeloma treatment and will be given two hours prior to standard treatment. Blood samples are taken at baseline, 15, 30, 60 and 120 minutes for microarray analysis.

Criteria for eligibility

Healthy Volunteers: No

Maximum Age: N/A

Minimum Age: 18 Years

Gender: Both

Criteria: Inclusion Criteria:

- Planned treatment for Multiple Myeloma (newly diagnosed as well as relapse and refractory disease) with one of the following chemotherapy regimens: 1) Highdose melphalan, 2) Bortezomib or 3) Dexamethasone

- 18 years or older.

- Understand and have the will to sign the informed consent.

Exclusion Criteria:

- Prior treatment with the study drug

- Received treatment with biphosphonates in the week prior to study treatment